溢多利(300381) - 2018 Q3 - 季度财报

Financial Performance - Net profit attributable to shareholders was ¥43,068,027.30, representing a significant increase of 91.22% year-on-year[8]. - Operating revenue for the period was ¥451,223,197.37, reflecting a growth of 33.64% compared to the same period last year[8]. - Basic earnings per share were ¥0.1059, up 91.16% year-on-year[8]. - The company reported a net profit of ¥74,400,650.33 for the year-to-date, which is a 71.48% increase compared to the same period last year[8]. - The company's operating income for the period reached ¥1,240,055,722.52, a 27.34% increase compared to ¥973,803,606.68 in the same period last year, primarily due to increased sales in the pharmaceutical sector[18]. - The net profit attributable to shareholders was ¥74,400,650.33, reflecting a significant growth of 71.48% from ¥43,388,361.54, driven by expanded market efforts and a rebound in industry prices[18]. - Operating profit for the current period was ¥55,607,003.36, compared to ¥29,864,045.93 in the previous period, reflecting an increase of approximately 86.3%[37]. - Net profit for the current period was ¥51,929,066.85, significantly higher than ¥28,756,802.46 from the previous period, marking an increase of around 80.5%[37]. Cash Flow - The net cash flow from operating activities for the year-to-date reached ¥180,581,384.00, a remarkable increase of 356.85%[8]. - The cash flow from operating activities generated a net amount of CNY 180,581,384.00, a substantial increase from CNY 39,527,128.64 in the previous period[50]. - The net cash flow from operating activities for the current period is ¥66,504,849.49, compared to a negative cash flow of ¥56,545,695.26 in the previous period, indicating a significant improvement[54]. - The total cash inflow from financing activities is ¥947,710,996.03, up from ¥684,301,409.74 in the previous period, reflecting a 38.5% increase[52]. - The cash outflow from financing activities increased to ¥954,870,263.42 from ¥516,480,085.35, resulting in a net cash flow from financing activities of -¥7,159,267.39, compared to ¥167,821,324.39 previously[52]. - The cash inflow from investment activities is ¥115,853,621.51, significantly higher than ¥67,886,838.10 in the previous period, marking an increase of approximately 70.7%[52]. - The cash outflow from investment activities decreased to ¥247,135,317.84 from ¥283,886,625.60, indicating a reduction of about 13%[52]. Assets and Liabilities - Total assets at the end of the reporting period reached ¥4,240,100,585.34, an increase of 10.27% compared to the end of the previous year[8]. - Current assets rose to CNY 2,124,703,534.65, up from CNY 1,724,292,460.65, indicating an increase of about 23.2%[28]. - Total liabilities increased to CNY 2,075,180,162.98 from CNY 1,755,055,076.63, representing a growth of approximately 18.3%[30]. - Owner's equity totaled CNY 2,164,920,422.36, up from CNY 2,090,216,569.28, indicating a slight increase of about 3.6%[30]. - The company’s long-term borrowings increased by 52.40% to ¥222,500,000.00 from ¥146,000,000.00, primarily due to increased borrowing by its subsidiary[18]. - The company’s inventory rose by 25.86% to ¥980,538,087.70 from ¥779,049,310.17, mainly due to increased stock of raw materials[18]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 15,491[12]. - The largest shareholder, Zhuhai Jindadi Investment Co., Ltd., held 34.82% of the shares, amounting to 141,615,094 shares[12]. - The company did not conduct any repurchase transactions among the top 10 shareholders during the reporting period[13]. Other Income and Expenses - The company reported a significant increase in other income, which rose by 102.91% to ¥24,325,966.88, primarily due to increased government subsidies received[18]. - Research and development expenses for the current period were ¥20,022,946.57, compared to ¥18,879,285.15 in the previous period, showing an increase of about 6%[35]. - Sales expenses rose to ¥44,842,226.89 from ¥34,632,589.09, indicating an increase of approximately 29.6%[35]. - Management expenses increased to ¥65,782,799.14 from ¥53,092,384.93, reflecting a growth of about 24%[35]. - The company reported an investment income of ¥898,585.35 for the current period, with no prior period data available for comparison[37]. Market Expansion - The company established a joint venture in Germany with Phytobiotics Futterzusatzstoffe GmbH to produce and sell enzyme preparations, with registration procedures currently underway[18].